SINICO, RENATO ALBERTO
 Distribuzione geografica
Continente #
NA - Nord America 18.800
EU - Europa 6.802
AS - Asia 4.669
SA - Sud America 368
AF - Africa 33
Continente sconosciuto - Info sul continente non disponibili 33
OC - Oceania 18
Totale 30.723
Nazione #
US - Stati Uniti d'America 18.367
SG - Singapore 1.865
IT - Italia 1.440
IE - Irlanda 1.295
CN - Cina 1.284
HK - Hong Kong 898
RU - Federazione Russa 890
SE - Svezia 869
DE - Germania 698
GB - Regno Unito 414
CA - Canada 396
UA - Ucraina 316
BR - Brasile 296
TR - Turchia 253
FI - Finlandia 250
AT - Austria 214
FR - Francia 179
VN - Vietnam 80
JP - Giappone 62
DK - Danimarca 61
IN - India 47
NL - Olanda 44
ID - Indonesia 40
ES - Italia 32
EU - Europa 30
MX - Messico 24
BE - Belgio 23
KR - Corea 21
AU - Australia 16
CL - Cile 16
IL - Israele 16
AR - Argentina 14
CO - Colombia 14
RO - Romania 14
BD - Bangladesh 12
PK - Pakistan 12
EC - Ecuador 10
IQ - Iraq 10
CH - Svizzera 9
CZ - Repubblica Ceca 9
UZ - Uzbekistan 9
EG - Egitto 8
GR - Grecia 8
IR - Iran 8
PE - Perù 7
VE - Venezuela 7
HU - Ungheria 6
SA - Arabia Saudita 6
BG - Bulgaria 5
MA - Marocco 5
PH - Filippine 5
PT - Portogallo 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
CR - Costa Rica 4
JO - Giordania 4
NO - Norvegia 4
TN - Tunisia 4
KE - Kenya 3
LB - Libano 3
LT - Lituania 3
MY - Malesia 3
PA - Panama 3
PL - Polonia 3
PS - Palestinian Territory 3
SC - Seychelles 3
TW - Taiwan 3
ZA - Sudafrica 3
A2 - ???statistics.table.value.countryCode.A2??? 2
JM - Giamaica 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
MD - Moldavia 2
MU - Mauritius 2
NP - Nepal 2
NZ - Nuova Zelanda 2
TH - Thailandia 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
DM - Dominica 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
HN - Honduras 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LV - Lettonia 1
MN - Mongolia 1
NG - Nigeria 1
NI - Nicaragua 1
Totale 30.716
Città #
Ann Arbor 3.897
Woodbridge 2.065
Chandler 1.378
Dublin 1.233
Houston 1.224
Singapore 1.104
Fairfield 1.043
Hong Kong 885
Dearborn 832
Wilmington 790
Ashburn 789
Jacksonville 783
Princeton 540
New York 509
Frankfurt am Main 487
Seattle 410
Milan 367
Cambridge 360
Santa Clara 283
Nanjing 254
Lawrence 243
Altamura 211
Vienna 197
Lachine 195
Boardman 169
Beijing 147
Lissone 123
Shanghai 119
San Diego 110
Ottawa 101
Andover 83
Nanchang 76
Council Bluffs 74
Shenyang 70
Guangzhou 67
Toronto 67
Hebei 60
Norwalk 59
Falls Church 53
Los Angeles 49
London 44
Jiaxing 42
Changsha 40
Helsinki 39
Washington 39
Tianjin 38
Chicago 37
Mountain View 36
Nuremberg 36
Jakarta 35
Jinan 35
Dong Ket 33
Zhengzhou 27
Hefei 26
Redmond 24
Rome 24
Hangzhou 22
Brussels 21
São Paulo 21
Kunming 20
Philadelphia 20
Munich 19
Pune 19
Tokyo 19
Florence 16
Kocaeli 16
Turin 15
Fremont 14
Lappeenranta 14
Tappahannock 13
Edmonton 12
Gwangmyeong 12
Paris 12
Sacramento 12
San Mateo 12
Belo Horizonte 11
Brescia 11
Kilburn 11
Wuhan 11
Auburn Hills 10
Phoenix 10
Taizhou 10
Caronno Pertusella 9
Detroit 9
Ningbo 9
Padova 9
Palermo 9
Bergamo 8
Brno 8
Rio de Janeiro 8
San Francisco 8
Santa Monica 8
Tashkent 8
Tel Aviv 8
Verona 8
Ankara 7
Berlin 7
Dallas 7
Fuzhou 7
Genoa 7
Totale 22.588
Nome #
Modifications in peripheral-blood lymphocyte subpopulations induced by plasmapheresis and immunosuppressive drugs 409
Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis 398
Combined Plasmatic and Tissue Approach to Membranous Nephropathy-Proposal of a Diagnostic Algorithm Including Immunogold Labelling: Changing the Paradigm of a Serum-based Approach 311
MALDI imaging in Fabry nephropathy: a multicenter study 306
Microscopic Polyangiitis 286
MALDI-MSI Approach to Renal Biopsies of Patients with Fabry Disease 275
MALDI-MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor (MIF) as a Possible Indicator of Response to Therapy in Membranous Nephropathy 274
Kidney Involvement 248
Rituximab as maintenance treatment for systemic Lupus ErythematosusA multicentre observational study of 147 patients 244
Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases 239
Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient) 234
135. ATHERO-THROMBOTIC AND VENOUS EVENTS (AVTE) IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A MULTICENTRE STUDY OF 573 ITALIAN PATIENTS 227
Neutrophil Extracellular Traps (NETs) profiles in patients with incident SLE and lupus nephritis 207
Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis 203
117. Prediction of Long-Term Evolutionary Profiles in Eosinophilic Granulomatosis with Polyangiitis (Churg– Strauss) Based on Baseline and Follow-Up Characteristics 201
Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis 201
Renal involvement in Churg-Strauss syndrome 198
162. Cluster analysis to explore clinical subclassification of eosinophilic granulomatosis with polyangiitis (churg–strauss) 196
Aberrant N-glycosylation patterns related to serum IgG subclasses in Idiopathic membranous nephropathy 192
Low-dose rituximab is poorly effective in patients with primary membranous nephropathy 189
Lack of IgA antineutrophil cytoplasmic antibodies in Henoch-Schönlein purpura and IgA nephropathy 189
HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome 188
Eosinophilic granulomatosis with polyangiitis (churg-straus syndrome) 187
Systemic Vasculitis and Pregnancy: A Multicenter Study on Maternal and Neonatal Outcome of 66 Prospectively Followed Pregnancies 176
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status 175
Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN) 171
Systemic Vasculitis and Pregnancy: a Multicenter Study On Maternal and Neonatal Outcome of 43 Prospectively Followed Pregnancies 171
Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome) 171
Anti-Neutrophil Cytoplasmic Antibodies Positivity and Anti-Leukotrienes in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Monocentric Study on 134 Italian Patients 170
Neutrophil Extracellular Traps in the Autoimmunity Context 164
[OP.4B.05] MIR-30A-3P EXPRESSION IN THE HEARTS OF DIABETIC RATS 163
Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): Planted antigens 161
Sneddon's syndrome: clinical and immunohistochemical findings 161
Systemic vasculitis and pregnancy: A multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies 160
354. EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS 159
RITUXIMAB AS MAINTENANCE THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS 157
Antinucleosome antibodies in primary antiphospholipid syndrome: A hint at systemic autoimmunity? 156
Multiple hepatic abscesses complicating continuous ambulatory peritoneal dialysis 155
255. Renal involvement in EGPA: a multicentre retrospective study of 63 cases 155
Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain 150
Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis 150
Immunology of membranous nephropathy: From animal models to humans 149
Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part 2): prospective study 149
Lymphocyte populations in the peripheral blood from patients with IgA nephropathy 147
The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy 147
Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study 147
Anticoagulant-related nephropathy: a pathological note 144
Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 143
FP165 Slowly progressive anca-associated glomerulonephritis: a multicentre study 143
ANCA-associated vasculitis in childhood: Recent advances 142
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients 141
Fcγ-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis 139
Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis [Position paper] 138
Outcome of Different Induction Regimens in Anca-Associated Glomerulonephritis According to the Histopathological Characteristics: the Reassess Study* 138
Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases 137
Polymeric IgA rheumatoid factor in idiopathic IgA mesangial nephropathy (Berger's disease) 136
Clinical evaluation of a rapid immunofluorescence test (IIFT) for diagnosis of ANCA-associated vasculitis 135
alpha 1-Antitrypsin (AAT) deficiency and ANCA-positive systemic vasculitis: genetic and clinical implications 135
ANCA with specificity for lactoferrin in systemic lupus erythematosus (SLE) 135
Role and clinical significance of rheumatoid factors in glomerulonephritis 135
New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group 135
Clinical significance of autoantibodies to myeloperoxidase in vasculitic syndromes 134
Microarray evaluation of allergen-specific IgE in eosinophilic granulomatosis with polyangiitis 133
Characterization of anti-myeloperoxidase antibodies in vasculitis 132
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies 132
Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI 130
Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis 130
Plasma-exchange and glomerulonephritis 129
Cluster analysis identifies distinct pathogenetic patterns in c3 glomerulopathies/immune complex–Mediated membranoproliferative GN 128
T-lymphocyte subsets in primary and secondary glomerulonephritis 128
Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome 128
Destructuring glomerular diseases with structured deposits: challenges in the precision medicine era 128
Definition of IgG Subclass-Specific Glycopatterns in Idiopathic Membranous Nephropathy: Aberrant IgG Glycoforms in Blood 127
Plasma-exchange in immunologically mediated glomerular diseases 127
Specificity of anti-neutrophil cytoplasm antibodies (ANCA) in vasculitic syndromes 127
Clinical significance of antineutrophil cytoplasmic autoantibodies with specificity for lactoferrin in renal diseases 126
Anti-glomerular basement membrane antibodies in the diagnosis of Goodpasture syndrome: A comparison of different assays 125
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide 124
Anti-endothelial cell antibodies in patients with Wegener's granulomatosis and micropolyarteritis 123
Spontaneous and pokeweed mitogen induced production of rheumatoid factor and immunoglobulins in type II essential mixed cryoglobulinaemia 120
Anti-C1q autoantibodies in lupus nephritis: Prevalence and clinical significance 120
Infectious serologies and autoantibodies in wegener's granulomatosis and other vasculitides: Novel associations disclosed using the rad BioPlex 2200 119
Effect of a continuous blood-cell separator and a polypropilene plasma filter on complement and platelet activation 118
The subclavian vein as an emergency vascular access for hemodialysis and plasma exchange 118
Simultaneous comprehensive multiplex autoantibody analysis for rapidly progressive glomerulonephritis 118
A reassessment of diagnostic criteria and treatment of idiopathic urticarial vasculitis: A retrospective study of 47 patients 117
ANCA-associated vasculitides (AAV) from the gender point of view 117
B lymphocyte subpopulations and T-cell subsets in primary chronic glomerulonephritis 116
L5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 116
FP216Renal involvement in EGPA : a multicentre retrospective study of 63 cases 116
Anti-M-Type Phospholipase A2 Receptor (PLA2R) Antibodies: Diagnostic Performance and Clinical Significance in Idiopathic Membranous Nephropathy (IMN) 115
Renal vasculitis 114
Novel Therapies in Takayasu Arteritis 114
Meningeal involvement in apparently ANCA-negative Wegener's granulomatosis: A role for PR3 capture-ELISA? [1] 113
Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells 113
CLINICAL FEATURES AND RENAL PROGNOSIS IN LUPUS NEPHRITIS PATIENTS UNDERGOING A REPEATED BIOPSY: RESULTS OF 103 RE-BIOPSIES IN 438 PATIENTS 113
European consensus statement on the terminology used in the management of lupus glomerulonephritis 112
Abnormalities of the IgA immune system in members of unrelated pedigrees from patients with IgA nephropathy 112
Immunoglobulin heavy chain switch region gene polymorphisms in glomerulonephritis 112
Role of monocytes in extracapillary glomerulonephritis (gn) - histochemical-study in 15 patients 112
Totale 16.078
Categoria #
all - tutte 122.362
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 122.362


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020632 0 0 0 0 0 0 0 0 0 145 365 122
2020/20213.779 118 120 469 425 235 388 519 375 381 294 184 271
2021/20222.909 153 295 405 193 210 197 143 152 134 167 311 549
2022/20234.857 662 1.283 345 373 420 819 48 227 410 40 146 84
2023/20243.713 127 127 134 146 526 951 762 94 328 59 58 401
2024/20254.976 483 899 322 374 782 249 626 360 812 69 0 0
Totale 32.032